| Literature DB >> 36033579 |
Guodong Jing1, Yukun Chen1, Xiaolu Ma1, Zhihui Li2, Haidi Lu1, Yuwei Xia3, Yong Lu4, Jianping Lu1, Fu Shen1.
Abstract
Detecting mismatch-repair (MMR) status is crucial for personalized treatment strategies and prognosis in rectal cancer (RC). A preoperative, noninvasive, and cost-efficient predictive tool for MMR is critically needed. Therefore, this study developed and validated machine learning radiomics models for predicting MMR status in patients directly on preoperative MRI scans. Pathologically confirmed RC cases administered surgical resection in two distinct hospitals were examined in this retrospective trial. Totally, 78 and 33 cases were included in the training and test sets, respectively. Then, 65 cases were enrolled as an external validation set. Radiomics features were obtained from preoperative rectal MR images comprising T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), contrast-enhanced T1-weighted imaging (T1WI), and combined multisequences. Four optimal features related to MMR status were selected by the least absolute shrinkage and selection operator (LASSO) method. Support vector machine (SVM) learning was adopted to establish four predictive models, i.e., ModelT2WI, ModelDWI, ModelCE-T1WI, and Modelcombination, whose diagnostic performances were determined and compared by receiver operating characteristic (ROC) curves and decision curve analysis (DCA). Modelcombination had better diagnostic performance compared with the other models in all datasets (all p < 0.05). The usefulness of the proposed model was confirmed by DCA. Therefore, the present pilot study showed the radiomics model combining multiple sequences derived from preoperative MRI is effective in predicting MMR status in RC cases.Entities:
Mesh:
Year: 2022 PMID: 36033579 PMCID: PMC9400426 DOI: 10.1155/2022/6623574
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.246
Figure 1Study flowchart. CH Cohort: Changhai Hospital; RJ Cohort: Ruijin Hospital Luwan Branch.
Figure 2Workflow for building the radiomics model.
Demographic and pathological data of the patients in both cohorts.
| Variables | CH cohort |
| RJ cohort |
| ||
|---|---|---|---|---|---|---|
| dMMR ( | pMMR ( | dMMR ( | pMMR ( | |||
| Gender (male/female) | 16/4 | 56/35 | 0.117 | 7/4 | 36/18 | 1.000 |
| Age (year) | 55.8 ± 9.9 | 57.1 ± 10.8 | 0.775 | 59.2 ± 11.9 | 60.1 ± 11.4 | 0.881 |
| BMI (kg/m2) | 23.2 ± 3.1 | 23.9 ± 3.8 | 0.660 | 24.1 ± 4.0 | 23.5 ± 3.5 | 0.747 |
| Histological type | ||||||
| Adenocarcinoma | 13 | 73 | 0.238 | 7 | 41 | 0.639 |
| Mucinous adenocarcinoma | 7 | 18 | 4 | 13 | ||
| Pathological T stage | ||||||
| T1-2 | 7 | 32 | 0.989 | 4 | 20 | 1.000 |
| T3-4 | 13 | 59 | 7 | 34 | ||
| Pathological N stage | ||||||
| N0 | 8 | 35 | 0.898 | 5 | 25 | 0.959 |
| N1-2 | 12 | 56 | 6 | 29 | ||
| Clinical M stage | ||||||
| M0 | 4 | 26 | 0.434 | 3 | 16 | 1.000 |
| M1 | 16 | 65 | 8 | 36 | ||
| Tumor location | ||||||
| Upper | 3 | 8 | 0.700 | 2 | 10 | 0.589 |
| Middle | 11 | 53 | 8 | 32 | ||
| Lower | 6 | 30 | 1 | 12 | ||
| Differentiation | ||||||
| Well | 3 | 14 | 0.213 | 1 | 10 | 0.330 |
| Moderate | 14 | 46 | 8 | 26 | ||
| Poor | 3 | 31 | 2 | 18 | ||
| Tumor deposit | ||||||
| No | 13 | 62 | 0.786 | 7 | 28 | 0.475 |
| Yes | 7 | 29 | 4 | 26 | ||
| Lymphovascular invasion | ||||||
| No | 12 | 47 | 0.498 | 8 | 29 | 0.408 |
| Yes | 8 | 44 | 3 | 25 | ||
| Perineural invasion | ||||||
| No | 12 | 63 | 0.425 | 5 | 30 | 0.540 |
| Yes | 8 | 28 | 6 | 24 | ||
| Tumor budding | ||||||
| No | 11 | 66 | 0.124 | 6 | 35 | 0.764 |
| Yes | 9 | 25 | 5 | 19 | ||
| KRAS | ||||||
| Wild type | 12 | 67 | 0.223 | 6 | 33 | 0.946 |
| Mutant type | 8 | 24 | 5 | 21 | ||
| NRAS | ||||||
| Wild type | 13 | 58 | 0.915 | 8 | 30 | 0.473 |
| Mutant type | 7 | 33 | 3 | 24 | ||
| BRAF | ||||||
| Wild type | 11 | 52 | 0.861 | 7 | 28 | 0.475 |
| Mutant type | 9 | 39 | 4 | 26 | ||
| CEA∗ | ||||||
| <5 ng/ml | 14 | 52 | 0.289 | 8 | 32 | 0.619 |
| ≥5 ng/ml | 6 | 39 | 3 | 22 | ||
| CA19-9∗ | ||||||
| <37 U/ml | 15 | 77 | 0.480 | 10 | 39 | 0.354 |
| ≥ 37 U/ml | 5 | 14 | 1 | 15 | ||
CH cohort: Changhai Hospital, training and test sets; RJ cohort: Ruijin Hospital Luwan Branch, validation set; BMI: body mass index; dMMR: deficient mismatch repair; pMMR: proficient mismatch repair; CEA: carcinoembryonic antigen; CA19-9: carbohydrate antigen 19-9. ∗Postoperative blood samples.
Comparisons of selected features between different MMR status.
| No. | Radiomics feature | Sequence | dMMR median (interquartile range) | pMMR median (interquartile range) |
|
| Coefficients∗∗ |
|---|---|---|---|---|---|---|---|
| 1 | Wavelet-LLH∗_ GLSZM_ zone variance | DWI | 5.131 (4.378-5.300) | 3.388 (2.950-3.968) | 3.521 | <0.001 | -0.075 |
| 2 | Wavelet-HLH∗_ GLSZM_ zone variance | DWI | 6.244 (5.800-8.000) | 5.000 (4.350-5.200) | 2.312 | 0.021 | -0.059 |
| 3 | Wavelet-HLH∗_ GLSZM_ large area high gray level emphasis | CE-T1WI | 4458.739 (3441.205-5718.022) | 2524.119 (2098.914-3682.686) | 2.505 | 0.012 | -0.052 |
| 4 | Gradient_ first order_ kurtosis | T2WI | 175982.000 (92672.000-213782.500) | 85442.833 (31509.800-107171.778) | 2.955 | 0.003 | -0.032 |
GLSZM: gray level size zone matrix. ∗The wavelet transform decomposes the tumor area image into low-frequency components (L) or high-frequency components (H) in the x, y, and z axes. †Mann–Whitney test. ∗∗The coefficients in LASSO algorithm.
Figure 3Heat map shows the distribution of radiomics features between the dMMR and pMMR groups. Each row in the heat map corresponds to a radiomics feature, each column corresponds to one patient. dMMR: deficient mismatch repair; pMMR: proficient mismatch repair.
Figure 4ROC curves for the SVM models. The performance of Modelcombination was better than those of other models (p < 0.05). (a) In the training set. (b) In the test set. (c) In the validation set.
ROC analysis of the radiomics models.
| ModelT2WI | ModelDWI | ModelCE-T1WI | Modelcombination | ||
|---|---|---|---|---|---|
| Training set | AUC | 0.768 | 0.670 | 0.718 | 0.910 |
| 95% CI | 0.659-0.856 | 0.554-0.772 | 0.605-0.814 | 0.823-0.963 | |
| Sensitivity | 0.844 | 0.328 | 0.844 | 0.844 | |
| Specificity | 0.643 | 1.000 | 0.643 | 0.929 | |
| Accuracy | 0.808 | 0.449 | 0.808 | 0.859 | |
| NRI∗ | 0.285 | 0.444 | 0.285 | / | |
|
| 0.028 | 0.043 | 0.002 | / | |
|
| |||||
| Test set | AUC | 0.707 | 0.568 | 0.691 | 0.901 |
| 95% CI | 0.523-0.852 | 0.385-0.738 | 0.507-0.840 | 0.746-0.977 | |
| Sensitivity | 0.407 | 0.667 | 0.926 | 1.000 | |
| Specificity | 1.000 | 0.667 | 0.500 | 0.667 | |
| Accuracy | 0.515 | 0.667 | 0.848 | 0.939 | |
| NRI∗ | 0.260 | 0.334 | 0.241 | / | |
|
| 0.019 | 0.042 | 0.042 | / | |
|
| |||||
| Validation set | AUC | 0.721 | 0.603 | 0.702 | 0.874 |
| 95% CI | 0.595-0.825 | 0.474-0.722 | 0.576-0.809 | 0.768-0.943 | |
| Sensitivity | 0.909 | 0.364 | 0.909 | 0.909 | |
| Specificity | 0.667 | 0.926 | 0.704 | 0.815 | |
| Accuracy | 0.708 | 0.831 | 0.738 | 0.831 | |
| NRI∗ | 0.148 | 0.434 | 0.111 | / | |
|
| 0.004 | 0.025 | 0.001 | / | |
Modelcombination: based on the combination of multisequences. ∗NRI: net reclassification improvement, Modelcombination compared with other models. ∗∗Compared with Modelcombination by DeLong test.
Figure 5Decision curve analysis of the prediction model in the validation set. The light gray line represents the assumption that all patients had dMMR. The dark gray line represents the hypothesis that no patients had dMMR. The red curve shows that with the probability of MMR ranging from 0.06 to 0.86, using the radiomics Modelcombination to predict MMR of RC would be beneficial than other radiomics models.